<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2015-01-13">13 January 2015</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Olivier</forename><surname>Benveniste</surname></persName>
							<email>olivier.benveniste@psl.aphp.fr</email>
						</author>
						<author>
							<persName><forename type="first">Werner</forename><surname>Stenzel</surname></persName>
						</author>
						<author>
							<persName><forename type="first">David</forename><surname>Hilton-Jones</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Marco</forename><surname>Sandri</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Olivier</forename><surname>Boyer</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Baziel</forename><forename type="middle">G M</forename><surname>Van Engelen</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department">Département de Médecine Interne et Immunologie Clinique</orgName>
								<orgName type="institution" key="instit1">Assistance Publique-Hôpitaux de Paris</orgName>
								<orgName type="institution" key="instit2">GH Pitié-Salpêtrière</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="institution">Université Pierre et Marie Curie</orgName>
								<address>
									<postCode>U974, DHU I2B</postCode>
									<settlement>Inserm, Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="department">Centre de Référence des Pathologies Neuromusculaires Paris Est</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="department">Institut de Myologie</orgName>
								<address>
									<settlement>Paris</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<orgName type="department">Department of Neuropathology</orgName>
								<orgName type="institution">Charité-Universitätsmedizin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">John Radcliffe Hospital</orgName>
								<address>
									<addrLine>West Wing</addrLine>
									<settlement>Oxford</settlement>
									<country key="GB">UK</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff6">
								<orgName type="department">Department of Biomedical Science</orgName>
								<orgName type="institution" key="instit1">Venetian Institute of Molecular Medicine</orgName>
								<orgName type="institution" key="instit2">University of Padova</orgName>
								<address>
									<settlement>Padua</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff7">
								<orgName type="institution">O. Boyer Inserm</orgName>
								<address>
									<postCode>U905</postCode>
									<settlement>Rouen</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff8">
								<orgName type="institution" key="instit1">University of Rouen</orgName>
								<orgName type="institution" key="instit2">IRIB</orgName>
								<address>
									<settlement>Rouen</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff9">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">Radboud University Medical Center</orgName>
								<address>
									<addrLine>Reinier Postlaan 4</addrLine>
									<settlement>Nijmegen</settlement>
									<country key="NL">The Netherlands</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2015-01-13">13 January 2015</date>
						</imprint>
					</monogr>
					<idno type="MD5">8FD0AD13595EEE2348CC0D8C2731EC8D</idno>
					<idno type="DOI">10.1007/s00401-015-1384-5</idno>
					<note type="submission">Received: 8 August 2014 / Revised: 5 January 2015 / Accepted: 6 January 2015 /</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:49+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Inclusion body myositis</term>
					<term>Pathogenesis</term>
					<term>Immune responses</term>
					<term>Autoimmunity</term>
					<term>Amyloid deposits</term>
				</keywords>
			</textClass>
			<abstract/>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p><s>Sporadic inclusion body myositis (sIBM) is the most frequent acquired progressive myopathy presenting over 50 years of age in Western populations <ref type="bibr" target="#b12">[13]</ref>, albeit rare.</s><s>For example, a recently published Dutch study from a tertiary referral centre identified only 64 patients from 7 specialized neuromuscular centres in a country with 16 million inhabitants <ref type="bibr" target="#b25">[26]</ref>, giving an estimated prevalence of 4.9 patients per million inhabitants in The Netherlands <ref type="bibr" target="#b12">[13]</ref>.</s><s>This may be an underestimate since sIBM can mimic other forms of myositis including polymyositis, hereditary myopathies of Abstract Sporadic inclusion body myositis (sIBM) is the most frequently acquired myopathy in patients over 50 years of age.</s><s>It is imperative that neurologists and rheumatologists recognize this disorder which may, through clinical and pathological similarities, mimic other myopathies, especially polymyositis.</s><s>Whereas polymyositis responds to immunosuppressant drug therapy, sIBM responds poorly, if at all.</s><s>Controversy reigns as to whether sIBM is primarily an inflammatory or a degenerative myopathy, the distinction being vitally important in terms of directing research for effective specific therapies.</s><s>We review here the pros and the cons for the respective hypotheses.</s><s>A possible scenario, which our experience leads us to favour, is that sIBM may start with inflammation within muscle.</s><s>The rush of leukocytes attracted by chemokines and cytokines may induce fibre injury and HLA-I overexpression.</s><s>If the protein degradation systems are overloaded (possibly due to genetic predisposition, particular HLA-I subtypes or ageing), amyloid and other protein deposits the limb girdle phenotype (see below) and the lower motor neuron variant of ALS.</s><s>sIBM is a disabling (but not in itself lethal) muscle disease with first symptoms typically presenting in the 6th decade of life <ref type="bibr" target="#b16">[17]</ref>.</s><s>The natural history of the condition is one of the relentless progression of weakness, with an estimated loss of strength between 3.5 and 5.5 % per year <ref type="bibr" target="#b16">[17,</ref><ref type="bibr" target="#b25">26]</ref>.</s><s>Pneumonia, secondary to immobility, respiratory muscle weakness and aspiration due to dysphagia, is a common terminal event <ref type="bibr" target="#b16">[17,</ref><ref type="bibr" target="#b25">26]</ref>.</s></p><p><s>There is a highly characteristic pattern of limb muscle involvement with selective weakness of finger flexion (Fig. <ref type="figure" target="#fig_0">1a, b</ref>) and knee extension (Fig. <ref type="figure" target="#fig_0">1c</ref>).</s><s>This pattern was noted by early investigators but considered of secondary importance to pathological features in establishing the diagnosis <ref type="bibr" target="#b41">[42]</ref>.</s><s>More recently, it has been proposed that clinical features are paramount and may allow the diagnosis of sIBM in the absence of what had previously been considered to be canonical pathological features (Table <ref type="table" target="#tab_0">1</ref>) <ref type="bibr" target="#b18">[19,</ref><ref type="bibr" target="#b81">82]</ref>.</s><s>Such criteria were assessed prospectively in a large cohort of IBM (n = 200) and non-IBM patients with other neuromuscular disorders (n = 171) <ref type="bibr" target="#b58">[59]</ref>.</s><s>They are highly specific (range 98-100 %) with a sensitivity of 77-84 % for probable IBM depending on the criteria used <ref type="bibr" target="#b18">[19,</ref><ref type="bibr" target="#b81">82]</ref>.</s><s>Furthermore in this study, the authors observed that the combination of finger flexor or quadriceps weakness and endomysial inflammation, and either invasion of non-necrotic muscle fibres or rimmed vacuoles permitted the diagnosis of sIBM with 90 % sensitivity and 96 % specificity <ref type="bibr" target="#b58">[59]</ref>.</s></p><p><s>Until recently, the diagnostic gold standard was considered to be certain pathological criteria.</s><s>These criteria <ref type="bibr" target="#b41">[42]</ref> include the presence of inflammatory infiltrates with mononuclear cell invasion of non-necrotic muscle fibres (partial invasion, Fig. <ref type="figure" target="#fig_1">2a</ref>), vacuolated muscle fibres (Fig. <ref type="figure" target="#fig_1">2b</ref>), and intracellular amyloid protein deposits [detected by fluorescent methods (Congo red, or p-FTAA dye (fluorescent thiophene) <ref type="bibr" target="#b51">[52]</ref>, Fig. <ref type="figure" target="#fig_1">2c</ref>] or 15-18 nm tubulofilaments in the cytoplasm or the nucleus by electron microscopy (Fig. <ref type="figure" target="#fig_1">2d</ref>).</s><s>Electron microscopy is rarely used in everyday practice and the original diagnostic criteria, without formal agreement, have been supplemented with the detection of various proteins by immunohistochemistry [e.g. with antibodies against phosphorylated tau, TDP43, or p62 (Fig. <ref type="figure" target="#fig_1">2 e, f</ref>) <ref type="bibr" target="#b21">[22,</ref><ref type="bibr" target="#b31">32]</ref> see below].</s></p><p><s>Furthermore, it has been noted frequently that the abovementioned canonical pathological features may be missing in patients with typical clinical features of the condition (leading to a sensitivity of only 11 % <ref type="bibr" target="#b58">[59]</ref>), particularly at first presentation, perhaps in part due to a small biopsy not reflecting the whole pathological picture <ref type="bibr" target="#b20">[21,</ref><ref type="bibr" target="#b23">24,</ref><ref type="bibr" target="#b31">32,</ref><ref type="bibr" target="#b76">77]</ref>.</s><s>Repeat biopsy later in the course of the disease may show canonical features absent at presentation, either because they evolve with time (see below), or reflecting sampling error.</s></p><p><s>Finally, Pestronk <ref type="bibr" target="#b74">[75]</ref> proposed classifying sIBM pathologically as an inflammatory myopathy with vacuoles, aggregates and mitochondrial pathology (IM-VAMP); but regarding the clinical features of sIBM, he did not estimate the specificity nor the sensitivity of such pathological criteria (which indeed has been the case with other proposed criteria).</s><s>Accordingly, mitochondrial abnormalities (COX negative and/or ragged red fibres) and partial invasion have been shown to provide strong evidence for the diagnosis of sIBM <ref type="bibr" target="#b20">[21,</ref><ref type="bibr" target="#b23">24]</ref>.</s><s>It has been also shown that the increased frequency of ragged red fibres, above the level predicted for normal ageing, is unique to sIBM and not observed in other inflammatory myopathies including polymyositis and dermatomyositis <ref type="bibr" target="#b78">[79]</ref>.</s></p><p><s>These diagnostic difficulties relate to the fact that the physiology of sIBM is not yet fully understood and that its proposed mechanisms are still debated <ref type="bibr" target="#b38">[39]</ref>.</s><s>In short, the canonical pathological features facilitated the initial clinical recognition of sIBM as a specific disorder.</s><s>Additional pathological features have since been recognized (accumulation of various proteins), but no individual pathological feature is diagnostic.</s><s>The stereotypical clinical features can allow diagnosis even in the absence of the typical histopathologic picture <ref type="bibr" target="#b20">[21]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Pathogenesis</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Amyloid component of sIBM</head><p><s>Included in the canonical pathological criteria, one of the main features of this disease is the abnormal accumulation of ubiquitinated proteinaceous congophilic inclusions within some muscle fibres.</s><s>This was first described in 1991 by Mendell et al. <ref type="bibr" target="#b61">[62]</ref> who studied the composition of cytoplasmic and intranuclear filamentous inclusions observed by electron microscopy (Fig. <ref type="figure" target="#fig_1">2d</ref>) on sIBM muscle biopsies and who observed amyloidogenic birefringent green deposits after Congo red staining.</s><s>They also observed that the number of amyloid-positive fibres correlated with the number of vacuolated fibres.</s><s>Perhaps presciently, the authors noted that "the association of amyloid deposits with autophagic vacuoles (i.e.</s><s>rimmed vacuoles) in IBM raises the likely possibility that the filaments represent a modification of a normal protein within an acidic degradative vacuolar compartment" <ref type="bibr" target="#b61">[62]</ref>.</s><s>Shortly after, Askanas et al. <ref type="bibr" target="#b8">[9,</ref><ref type="bibr" target="#b9">10]</ref> showed by immunohistochemistry that inclusions within vacuolated fibres were immunoreactive with anti-β-amyloid antibodies, and by immunogold electron microscopy that β-amyloid protein immunoreactivity was localized in proximity to cytoplasmic tubulofilaments <ref type="bibr" target="#b8">[9,</ref><ref type="bibr" target="#b9">10]</ref>.</s><s>The amyloid-β precursor protein (AβPP) overproduction is not yet clarified (for review <ref type="bibr" target="#b11">[12]</ref>).</s><s>AβPP is then cleaved to Aβ40 or Aβ42, and oligomers of these proteins may form subsequently <ref type="bibr" target="#b7">[8]</ref>.</s><s>We will use the term 'β-amyloid' throughout the review.</s><s>These β-amyloid protein deposits are also shown to be accompanied by an increase in plasma Aβ42 protein in sIBM blood samples as compared to polymyositis patients and control subjects <ref type="bibr" target="#b0">[1]</ref>.</s><s>Nevertheless, this increase is also noticed in the blood of dermatomyositis (DM) patients limiting the value of this potential biomarker.</s><s>Again by immunostaining, Askanas et al. <ref type="bibr" target="#b10">[11]</ref> demonstrated the presence of numerous further molecules known to be associated with specific degenerative processes, particularly of the central nervous system such as phosphorylated tau, ubiquitin, α-synuclein and prion protein (for review see <ref type="bibr" target="#b7">[8]</ref>).</s><s>These abnormal protein aggregates are observed within muscle fibres in the form of plaque-like or dotty inclusions <ref type="bibr" target="#b7">[8]</ref>.</s><s>However, protein deposition may not have the same functional implications as in the central nervous system.</s><s>β-amyloid deposits, for example, are mostly found extracellularly in Alzheimer's disease while they are intracellular in muscle fibres of sIBM patients.</s></p><p><s>Before considering further what might be called the 'amyloid hypothesis', it must be noted that not all investigators have concluded that the accumulation of proteins associated with neurodegeneration is of specific significance.</s><s>For example, using a proteomic approach, Parker et al. <ref type="bibr" target="#b72">[73]</ref> did not find accumulation of such proteins in sIBM nor did they detect even one peptide from β-amyloid.</s><s>This lack of detection could be related to limited sensitivity of current proteomic technology <ref type="bibr" target="#b94">[95]</ref>.</s></p><p><s>Nevertheless, defenders of the theory of β-amyloidmediated sIBM myofiber injury have tried to understand the physiology of the amyloid deposits by studying protein degradation pathways (Fig. <ref type="figure">3</ref>).</s><s>One of the two pathways for protein degradation is the 26S-proteasome; notably, it is responsible for the degradation of abnormal or damaged proteins.</s><s>The 26S proteasome can be divided into two subcomplexes, the core particle (20S) and the regulatory particle (19S).</s><s>The 19S assists in deubiquitination, and unfolds ubiquitinated protein substrates that are subsequently translocated into an enclosed cavity formed by the 20S unit.</s><s>Here, a variety of catalytic sites degrade the substrate into short peptides that are subsequently broken down to amino acids by peptidases and recycled by the cell.</s><s>In sIBM muscle biopsies, 26S proteasome subunits (19S and 20S) co-localized by immunodetection with phosphorylated tau, ubiquitin and/or β-amyloid protein deposits <ref type="bibr" target="#b34">[35]</ref>.</s><s>Paradoxically, even though both proteasome subunits were upregulated in sIBM muscle, the three main proteolytic activities (trypsin-like, chymotrypsin-like and peptidyl-glutamyl-peptide hydrolytic) of the 20S were dramatically reduced <ref type="bibr" target="#b34">[35]</ref>.</s><s>This is consistent with the fact that proteasomes can destroy only soluble proteins while aggregates are mainly removed by autophagy <ref type="bibr" target="#b36">[37]</ref>.</s></p><p><s>The second pathway of protein degradation is autophagy (Fig. <ref type="figure">3</ref>).</s><s>A portion of the cytoplasm, organelles, proteins and protein aggregates are engulfed by a double-layered membrane to form a vesicle that is called an autophagosome.</s><s>Next, autophagosomes dock and fuse with lysosomes to form autolysosomes where the cargo is degraded by acidic hydrolases.</s><s>The degradation products are transported to the cytosol where they are utilized to build new organelles/proteins or for energy production <ref type="bibr" target="#b87">[88]</ref>.</s><s>Autophagy can be selective and can remove specifically damaged organelles and/or protein aggregates.</s><s>Different mechanisms are involved in the selective recognition of the cargo and some are depicted in Fig. <ref type="figure">3</ref>. Failure of autophagy leads to accumulation of cargo and autophagy substrates such as p62/SQSTM1, NBR1 and tau.</s><s>Autophagosomes containing amyloid precursor protein and β-amyloid proteins can be observed at increased frequency in muscle fibres of sIBM muscle biopsies, but not in non-myopathic muscle or in non-vacuolated myopathic controls <ref type="bibr" target="#b59">[60]</ref>.</s><s>Moreover, Nogalska et al. <ref type="bibr" target="#b66">[67]</ref> observed markers of autophagy induction such as LC3-II in sIBM muscle, but at the same time, a significant decrease of lysosomal enzyme activities of cathepsins D and B, leading to the conclusion that autophagy is also impaired during sIBM.</s><s>The mechanism explaining why autophagy is impaired, and at which level the autophagy flux is blocked in sIBM, is still not fully understood (see Fig. <ref type="figure">3</ref>).</s><s>It is important now to determine whether such failure is secondary to inflammation or is a direct consequence of excessive protein misfolding and aggregation.</s></p><p><s>Concomitantly p62, a shuttle protein transporting poly-ubiquitinated proteins for both the proteasomal and lysosomal degradation pathways accumulates within muscle fibres into aggregates that are positive for phosphorylated tau <ref type="bibr" target="#b67">[68]</ref>.</s><s>This feature is consistent with the failure of autophagy.</s><s>Indeed, one of the most important markers of autophagy block is the presence of p62-positive inclusions <ref type="bibr" target="#b88">[89]</ref> (Fig. <ref type="figure">3</ref>).</s><s>Accumulation of another protein, TDP43 <ref type="bibr" target="#b31">[32,</ref><ref type="bibr" target="#b86">87]</ref>, which is one component of the ubiquitinated inclusions in the brain of patients with, for example, frontotemporal dementia, may also relate to proteasome dysfunction Fig. <ref type="figure">3</ref> In sIBM, misfolded proteins start to accumulate into aggregates that are positive for P62 and NBR1.</s><s>The presence of P62-positive aggregates is a consequence of impaired protein clearance of proteasome and autophagy/lysosome (Ly) systems that further impacts on their activities.</s><s>Overload of the autophagy system with subsequent exhaustion, aspecific absorption and sequestration of the proteasome on the surface of inclusions describe how aggregates negatively affect these systems.</s><s>Autophagy is characterized by membranes that are committed to growth, thus becoming double membrane vesicles, named autophagosome, that surround a 'portion' of cytoplasm, organelles, glycogen and protein aggregates.</s><s>Autophagy is triggered by the activation of a regulatory complex (containing Vps34, Beclin 1, Vps15, Ambra1, Atg14) that induces LC3 recruitment to the nascent autophagosome (isolation membrane).</s><s>Selective removal of organelles including mitochondria (mitophagy, a specific form of autophagy) requires several signals.</s><s>For example in mitophagy, Bnip3 factors are recruited on damaged mitochondria and by binding LC3 allow the recruitment of the vesicle on the surface of the altered mitochondria.</s><s>Proteins that are committed for lysosomal degradation are labelled by polyubiquitin chains and delivered to the autophagosome by the p62/NBR1 scaffold proteins that bind LC3.</s><s>Finally, upon autophagosome fusion with lysosome the cargo is destroyed and constituents are recycled by the cell to rebuild organelles/proteins or for energy purposes.</s><s>Whether inflammation triggers protein misfolding aggregation or blocks the autophagy and proteasome system is still an open issue and will certainly be subject of future studies.</s><s>Dotted lines represent unknown mechanisms (Ub = ubiquitin) 1 3 <ref type="bibr" target="#b100">[101]</ref>.</s><s>It has been shown that the conditional knock-out of the proteasome (but not of autophagy) in mice induced the accumulation of TDP43 <ref type="bibr" target="#b47">[48]</ref>.</s><s>The presence of p62 and/or TDP43 accumulations, demonstrated by immunostaining, is now recognized as one of the most sensitive pathological findings in sIBM <ref type="bibr" target="#b21">[22,</ref><ref type="bibr" target="#b31">32]</ref>.</s><s>However, the best diagnostic sensitivity (93 %) and specificity (100 %) were obtained by the combination of characteristic p62 aggregates and increased sarcolemmal and internal major histocompatibility complex class I expression or endomysial T cell infiltrates <ref type="bibr" target="#b21">[22]</ref>.</s></p><p><s>Thus, in sIBM, accumulation of aggregates seems to be related to proteasome and autophagy dysfunctions, but with what pathophysiological consequences?</s><s>Various mouse models have attempted to provide further insight.</s><s>A double transgenic mouse, overexpressing APP and the presenilin-1 gene under the dependence of a muscle specific promotor, showed increased Aβ42 levels in skeletal muscle and exacerbation of inclusion body myositis-like pathology and motor deficits <ref type="bibr" target="#b49">[50]</ref>.</s><s>Moreover, the overexpression of the proteolytic fragments of mutant (D187N/Y) plasma gelsolin (familial Finnish amyloidosis) also leads to muscle weakness, the appearance of vacuoles and an increase in proteasome and autophagy markers <ref type="bibr" target="#b70">[71]</ref>.</s><s>Specific overexpression of a transgenic heavy chain of major histocompatibility class I (MHC-I) in myofibers leads to a severe myopathy in immunocompetent mice with induction of stress of the endoplasmic reticulum <ref type="bibr" target="#b64">[65,</ref><ref type="bibr" target="#b65">66]</ref>.</s><s>It was further shown that these changes also occur in immunodeficient mice, indicating that in mice this myopathy may arise without any contribution of the adaptive immune system (i.e.</s><s>presentation of muscle autoantigens to autoreactive CD8 + T cells by MHC-I molecules) <ref type="bibr" target="#b35">[36]</ref>.</s><s>Interestingly in this report, muscle of sIBM patients presented similar proteomic features of endoplasmic reticulum stress in a fashion that was dependent on the level of intracellular accumulation of MHC-I molecules <ref type="bibr" target="#b35">[36]</ref>.</s><s>It is likely that, when the protein degradation systems are overloaded (e.g.</s><s>here by the MHC-I overexpression), proteins are misfolded and/or ubiquitinated and their accumulation causes a vacuolar myopathy <ref type="bibr" target="#b35">[36]</ref>.</s><s>This situation is also observed in patients with a form of hereditary inclusion body myopathy (hIBM) due to p97/VCP mutations, which is another molecular complex responsible for the regulation of protein degradation through the proteasome and autophagy <ref type="bibr" target="#b48">[49]</ref>.</s><s>Here again, P62 and TDP-43 accumulate in the cytoplasm of p97/VCP mutant-expressing cells and transgenic mouse muscle <ref type="bibr" target="#b47">[48]</ref>.</s><s>Furthermore in sIBM, the β-amyloid β42 deposits co-localized with dysferlin, which is absent from the sIBM muscle fibre sarcolemma (contrary to normal muscle where dysferlin is localized at the sarcolemma) <ref type="bibr" target="#b22">[23]</ref>.</s><s>Knowing that this protein is involved in the sarcolemmal repair of muscle fibres <ref type="bibr" target="#b15">[16]</ref>, this interaction may aggravate the myopathy.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Inflammatory component of sIBM</head><p><s>The second pathological hallmark of sIBM is the presence of inflammatory infiltrates (Fig. <ref type="figure" target="#fig_2">4</ref>).</s><s>These infiltrates are rich in lymphocytes (mostly CD8 + T cells, Fig. <ref type="figure" target="#fig_2">4a</ref>) and macrophages (Fig. <ref type="figure" target="#fig_2">4b</ref>), while CD4 + T cells (Fig. <ref type="figure" target="#fig_2">4c</ref>) and B lymphocytes (Fig. <ref type="figure" target="#fig_2">4d</ref>) are less abundant.</s><s>CD8 + T cell-and macrophage-rich infiltrates are regularly observed invading non-necrotic fibres (Fig. <ref type="figure" target="#fig_1">2a</ref>) <ref type="bibr" target="#b6">[7]</ref>.</s><s>Invading CD8 + T cells express co-stimulatory molecules such as inducible T cell co-stimulator (ICOS) which may promote lymphocyte activation by providing secondary signals to T cells in addition to T cell receptor stimulation by antigen, and elicit cytotoxic function markers such as perforin <ref type="bibr" target="#b92">[93]</ref>.</s><s>CD8 + T cells can be expanded ex vivo from muscle of polymyositis and sIBM patients.</s><s>These clones show cytotoxic activity against autologous myotubes in vitro <ref type="bibr" target="#b45">[46]</ref>.</s><s>We have previously demonstrated shared oligoclonal expansions of CD8 + cells in both peripheral blood and muscle inflammatory infiltrates of sIBM patients (Fig. <ref type="figure" target="#fig_2">4e</ref>) <ref type="bibr" target="#b30">[31]</ref>.</s><s>These clones persist in repeated muscle biopsies <ref type="bibr" target="#b3">[4]</ref>, as they do in polymyositis <ref type="bibr" target="#b17">[18]</ref>.</s><s>Finally, these expanded cytotoxic CD8 + T cells become CD28 null <ref type="bibr" target="#b1">[2,</ref><ref type="bibr" target="#b71">72]</ref>, a phenotype of chronically activated and terminally differentiated T cells.</s><s>To develop into functional cytotoxic effectors, CD8 + T cells must recognize, via their T cell receptor, specific antigenic epitopes presented by the target cells in a MHC-I-restricted manner.</s><s>Not surprisingly then, diffuse overexpression of MHC-I is observed on the surface of myofibers in sIBM <ref type="bibr" target="#b32">[33]</ref> and is even more prominent in sIBM compared to other forms of myositis <ref type="bibr" target="#b73">[74]</ref>, allowing the presentation of (today still unknown) antigens to effector T cells.</s><s>The attack of myofibers by cytotoxic T cells seems to be related to local inflammation associated with the induction of the interferon gamma receptor, up-regulation of several interferon gamma-induced genes <ref type="bibr" target="#b46">[47]</ref> and presence of several cytokines such as IFN-γ, IL-1β, TNF-α <ref type="bibr" target="#b69">[70]</ref> and tumour necrosis factor-like weak inducer of apoptosis (TWEAK) <ref type="bibr" target="#b63">[64]</ref>.</s></p><p><s>On the other hand, immuno-regulatory second signals such as programmed death ligand 1 (PD-L1, formerly referred to as B7-H1) are also triggered, presumably as a negative feedback loop.</s><s>PD-L1 is expressed in polymyositis, dermatomyositis and sIBM muscle fibres but not in normal muscle.</s><s>Staining is predominantly localized (in muscle fibres as well as mononuclear cells) to areas of strong inflammation <ref type="bibr" target="#b101">[102]</ref>.</s><s>Furthermore, cultured human myoblasts express high levels of PD-L1 after stimulation with the inflammatory cytokine IFN-γ <ref type="bibr" target="#b101">[102]</ref>.</s><s>Another mechanism of control of the specific immune responses relates to regulatory T cells (Treg).</s><s>Congenital or acquired Treg deficiency causes multi-organ autoimmune disease in mice and in humans <ref type="bibr" target="#b19">[20,</ref><ref type="bibr" target="#b54">55,</ref><ref type="bibr" target="#b97">98,</ref><ref type="bibr" target="#b102">103]</ref>.</s><s>We were the first to 1 3 describe a Treg deficiency (but with normal function) in the peripheral blood of sIBM patients <ref type="bibr" target="#b1">[2]</ref>.</s><s>Indeed, we observed in 22 sIBM patients, compared to 22 sex-and age-matched healthy subjects, that sIBM patients had a decreased frequency of circulating regulatory T cells (CD4 + CD25 + CD1 27 low FOXP3 + , 6.9 ± 1.7 %; vs. 5.2 ± 1.1 %, p = 0.01) that displayed normal suppressor function <ref type="bibr" target="#b1">[2]</ref>.</s></p><p><s>Also recently, new arguments, coming from microarray analyses, have shown that it is not only cellular responses that are involved in sIBM but also humoral responses <ref type="bibr" target="#b40">[41]</ref>.</s><s>In contrast to normal muscle, immunoglobulin genes are the most abundant transcripts in sIBM, and antibodysecreting plasma cells (CD138 + ) are frequently observed (Fig. <ref type="figure" target="#fig_2">4f</ref>) in higher numbers than B cells which remain rather rare (Fig. <ref type="figure" target="#fig_2">4d</ref>) <ref type="bibr" target="#b40">[41]</ref>.</s><s>Recently, Ray et al. <ref type="bibr" target="#b77">[78]</ref> isolated single plasma cells by microdissection directly from IBMderived muscle tissue sections and analysed a series of recombinant immunoglobulins produced from these cells; the muscle molecular target of these antibodies appeared to be desmin.</s><s>Of note, anti-desmin antibodies have been described in different autoimmune conditions (such as lupus and autoimmune thrombocytopenic purpura <ref type="bibr" target="#b93">[94,</ref><ref type="bibr" target="#b96">97]</ref>) and might not be of any specific significance, but in inherited desminopathies, clinic-pathological features include distal involvement and rimmed vacuoles with amorphous deposits <ref type="bibr" target="#b37">[38]</ref>.</s><s>These desmin aggregates co-localized with ubiquitinated proteins (and notably mutant ubiquitin which is resistant to proteasome degradation) and p62 <ref type="bibr" target="#b68">[69]</ref>.</s><s>It is therefore questionable whether those intramuscular secreted anti-desmin antibodies participate in proteasome dysfunction.</s></p><p><s>Despite the clear evidence of global immune activation in sIBM, the question remains as to whether sIBM is primarily an inflammatory or a degenerative myopathy.</s><s>If amyloid is the consequence of a primary immune reaction, including secretion of cytokines that increase MHC-I expression to such an extent that protein degradation capabilities are overloaded <ref type="bibr" target="#b35">[36]</ref>, then targeted immune intervention (e.g.</s><s>biotherapies) at an early stage of the disease may be useful.</s><s>On the contrary, if sIBM is primarily a degenerative disease in which accumulation of unfolded proteins causes a secondary immune reaction, immunointervention may be of limited, if any, benefit.</s><s>Thus, we will review below the pros and the cons for both hypotheses.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Arguments for degeneration as initial event/trigger</head><p><s>The main argument comes from the lack of significant beneficial clinical effect from conventional immunosuppressant drug therapy.</s><s>Eight prospective double-blind studies have shown that conventional immunosuppressants (corticosteroids or methotrexate) or immunomodulatory regimens (polyvalent immunoglobulins, beta interferon, oxandrolone) have minimal or no benefit for sIBM patients <ref type="bibr" target="#b13">[14,</ref><ref type="bibr" target="#b27">28,</ref><ref type="bibr" target="#b29">30,</ref><ref type="bibr" target="#b42">43,</ref><ref type="bibr" target="#b43">44,</ref><ref type="bibr" target="#b56">57,</ref><ref type="bibr" target="#b83">84,</ref><ref type="bibr" target="#b99">100]</ref>.</s><s>It has to be noted that the limited number of validated and sensitive disease activity and damage assessment tools specific for sIBM <ref type="bibr" target="#b44">[45]</ref> are clearly a limitation in evaluating the clinical trial data, and probably all of these studies were underpowered, in terms of numbers and duration.</s><s>Thus, we cannot be absolutely certain of complete lack of response to such treatments, although our own observations strongly support the lack of clinical efficacy.</s><s>We undertook a long-term observational study of 136 sIBM patients of whom 71 patients (52 %) received immunosuppressive treatment [prednisone in 92 %, associated, in 65 %, with other immunomodulatory drugs (intravenous immunoglobulins, methotrexate or azathioprine)] for a median duration of 3.5 years <ref type="bibr" target="#b16">[17]</ref>.</s><s>At the last assessment, treated patients had not only not improved, but were more severely affected, based on disability scales (Walton p = 0.007, RMI p = 0.004) and on the sIBM weakness composite index (p = 0.04), than those who were not treated.</s><s>The first stage of disease progression, towards handicap in walking, also occurred more rapidly among patients receiving immunosuppressive treatments (HR = 2.0, p = 0.002).</s><s>We therefore concluded that immunosuppressive treatments do not ameliorate, and may even aggravate, the natural course of sIBM <ref type="bibr" target="#b16">[17]</ref>.</s><s>We have to note that there are other presumed autoimmune conditions that show similar resistance to immunosuppressant therapy, notably multiple sclerosis (in its primary progressive form) and scleroderma.</s><s>The immunosuppressant resistance may then not be a definite argument against the autoimmune nature of sIBM.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Arguments for inflammation as initial event/trigger</head><p><s>sIBM has been frequently described in association with other autoimmune disorders <ref type="bibr" target="#b14">[15,</ref><ref type="bibr" target="#b23">24,</ref><ref type="bibr" target="#b52">53]</ref>.</s><s>For instance, in a Dutch study of 52 sIBM patients, 17 patients (33 %) had associated autoimmune disorders including autoimmune thyroiditis (n = 6), rheumatoid arthritis (n = 4) and Sjögren syndrome (n = 4), with 3 patients with multiple autoimmune disorders <ref type="bibr" target="#b14">[15]</ref>.</s><s>The prevalence of autoantibodies is also increased in sIBM <ref type="bibr" target="#b23">[24,</ref><ref type="bibr" target="#b79">80]</ref>.</s><s>For instance, in an Australian study, 51 sIBM patients were compared to 198 controls and the frequency of positive antinuclear autoantibodies was higher in sIBM (29.4 vs. 8.6 %, p &lt; 0.001), and among antibodies against extractable nuclear antigens (in order of their frequency), anti-SSA/Ro-52 or Ro-60, SSB/ La, RNP-A or C, and PM-Scl75 were statistically more frequently observed in sIBM patients <ref type="bibr" target="#b79">[80]</ref>.</s></p><p><s>Recently, apparently sIBM-specific autoantibodies have been described.</s><s>An antibody recognizing a 43 kD antigenic target was found in the serum of 13 out of 25 sIBM patients but not in 40 controls (healthy subjects or patients with other inflammatory myopathies) <ref type="bibr" target="#b85">[86]</ref>.</s><s>The antigenic target of this sIBM associated autoantibody has been identified by two independent teams as cytosolic 5′-nucleotidase 1A <ref type="bibr" target="#b55">[56,</ref><ref type="bibr" target="#b75">76]</ref> an enzyme involved in nucleotide metabolism which is expressed at a relatively high level in skeletal muscle.</s><s>Anti-NT5C1A autoantibodies were present in 33 % <ref type="bibr" target="#b75">[76]</ref> and 34 % <ref type="bibr" target="#b55">[56]</ref> of sIBM patients, as compared to ≤5 % in polymyositis and dermatomyositis <ref type="bibr" target="#b55">[56,</ref><ref type="bibr" target="#b75">76]</ref>.</s><s>Nonetheless, the specificity of this new anti-NT5C1A autoantibody for the diagnosis of sIBM has not yet been fully evaluated and further studies are required, particularly in other groups of connective tissue diseases such as rheumatoid arthritis, lupus and systemic sclerosis.</s><s>To date, our unpublished data suggests that this autoantibody can also be present in rheumatologic disorders such as lupus and Sjögren syndrome, so its specificity may not be as high as initial reports, in a more restricted group of patients, suggested.</s></p><p><s>Evidence for a sIBM-prone immunogenetic background comes from observations of a strong association with prominent alleles of HLA class I or II (such as alleles B8 and notably DRbeta1*0301) <ref type="bibr" target="#b14">[15,</ref><ref type="bibr" target="#b52">53,</ref><ref type="bibr" target="#b80">81]</ref>, a situation not observed in hereditary inclusion body myopathies <ref type="bibr" target="#b52">[53]</ref>.</s></p><p><s>From a pathological point of view, Pruitt et al. <ref type="bibr" target="#b76">[77]</ref> have shown that in muscle biopsies derived from 31 patients, the frequency of invaded fibres (mean 24.3/1,000) was several fold higher than that of congo red positive fibres (mean 3.1/1,000) or that of necrotic fibres (mean 3.1/1,000), and they concluded on the importance of an immune-mediated mechanism in sIBM.</s><s>Sarcolemmal HLA class I expression, which is absent in normal muscle <ref type="bibr" target="#b5">[6]</ref>, is upregulated in myositis in general <ref type="bibr" target="#b26">[27]</ref> and in sIBM in particular <ref type="bibr" target="#b73">[74]</ref>.</s><s>The immunohistological detection of HLA class I on the sarcolemma is thus considered to be a marker of myositis.</s><s>In sIBM, the prevalence of HLA staining on muscle fibres is higher compared to dermatomyositis and polymyositis: expression of HLA class I was found in 67 % of muscle biopsies from patients with dermatomyositis, in 61 % with polymyositis, and in 96 % with sIBM (on 208 analysed biopsies) <ref type="bibr" target="#b73">[74]</ref>.</s></p><p><s>Finally, and in contrast to the observations noted above concerning the outcome of prospective, double-blind, studies of immunosuppressive therapies in sIBM, two clinical trials, which included only a small number of patients, suggested that massive immunosuppression can lead to strength stabilization.</s><s>The first compared six patients treated with anti-T lymphocyte globulin and methotrexate, with five patients treated with methotrexate only.</s><s>The latter showed a significant loss of strength after 12 months but the anti-T lymphocyte globulin group remained stable <ref type="bibr" target="#b57">[58]</ref>.</s><s>In the second study, 13 patients were evaluated by quantitative muscle strength testing to determine their natural history over 1 year.</s><s>These patients were then treated by alemtuzumab (Campath™) and showed a transient stabilization of strength after 6 months <ref type="bibr" target="#b28">[29]</ref>.</s><s>Even if the results of the latter study have been debated <ref type="bibr" target="#b39">[40]</ref>, both studies suggest the possible involvement of adaptive immune responses in disease progression.</s></p><p><s>As indicated above, sIBM is accompanied by degenerative protein accumulations, and deficient protein degradation pathways (both proteasomal and lysosomal) and one accumulated protein candidate might be HLA class I <ref type="bibr" target="#b35">[36]</ref>.</s><s>This situation exists in patients with a hereditary inclusion body myopathy due to p97/VCP mutation, which is a complex responsible for the regulation of protein degradation through these two pathways, but this hereditary inclusion body myopathy is not accompanied by significant inflammation <ref type="bibr" target="#b48">[49]</ref>, neither the animal model <ref type="bibr" target="#b47">[48]</ref>.</s><s>In the same vein, the other classical hereditary inclusion body myopathy is caused by UDP-N-acetylglucosamine-2-epimerase/N-acetylmannosamine kinase (GNE) gene mutation (leading to quadriceps-sparing myopathy).</s><s>GNE encodes for a key enzyme in sialic acid biosynthesis and the myopathy is associated with the formation of autophagic vacuoles <ref type="bibr" target="#b60">[61]</ref>.</s><s>But this vacuolar myopathy is essentially not accompanied by muscle inflammation <ref type="bibr" target="#b24">[25]</ref>, except in three cases, from two families <ref type="bibr" target="#b4">[5,</ref><ref type="bibr" target="#b53">54]</ref>.</s><s>Nevertheless and despite the general absence of inflammation, iNOS and αB-crystallin, two markers of cell stress, are present in normal appearing fibres of GNE patients and correlated with pro-inflammatory markers (such as IL-6), which remained expressed at levels comparable to control muscles <ref type="bibr" target="#b33">[34]</ref>.</s><s>Furthermore, mouse models of GNE do not show features of inflammation <ref type="bibr" target="#b104">[105]</ref>.</s><s>Experimentally, a transgenic mouse model of Finnish-type familial amyloidosis associated with gelsolin amyloidosis in skeletal muscle (with the gelsolin transgene under the control of a muscle specific promoter), is associated with amyloid deposits with foci of mononuclear cell infiltration <ref type="bibr" target="#b70">[71]</ref>.</s><s>In a model with genetically augmented Aβ42 levels in skeletal muscle, there was no inflammation <ref type="bibr" target="#b49">[50]</ref>.</s><s>Hence, degenerative processes in muscle induce cell stress but do not clearly and unequivocally elicit inflammation.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Influence of inflammation on amyloid deposits and/or muscle atrophy</head><p><s>In a sIBM transgenic mouse model, that is marked by enhanced levels of Aβ1-42 in skeletal muscle (of note, with no obvious muscle inflammatory infiltrates) <ref type="bibr" target="#b49">[50]</ref>, the long-term influence of inflammation, induced by chronic lipopolysaccharide injections, included increased Aβ generation and enhanced tau phosphorylation <ref type="bibr" target="#b50">[51]</ref>.</s></p><p><s>In muscle biopsies of sIBM patients, compared to other forms of myositis, Schmidt et al. <ref type="bibr" target="#b89">[90]</ref> found that expression of the mRNA of β-amyloid precursor protein significantly and consistently correlated with inflammation and enhanced mRNA levels of chemokines (CXCL-9, CCL-4 and CCL-3) and IFN-γ.</s><s>To assess the influence of inflammation on β-amyloid accumulation, these authors performed in vitro experiments in human myotubes, and showed that exposure to IL-1β caused up-regulation of APP with subsequent intracellular aggregation of β-amyloid <ref type="bibr" target="#b89">[90]</ref>.</s><s>Furthermore, exposure to interleukin-1β, in combination with interferon-γ induced intracellular production of nitric oxide, was associated with necrotic cell death in muscle cells <ref type="bibr" target="#b90">[91]</ref>.</s><s>Hence, inflammation in muscle can elicit amyloid accumulation.</s><s>On the other hand, by studying biopsies of sIBM patients before and after prednisone ± polyvalent immunoglobulins, the same group <ref type="bibr" target="#b105">[106]</ref> showed that these treatments decrease inflammation in muscle, but do not significantly suppress myotoxic and cell stress mediators such as nitric oxide.</s></p><p><s>As we have seen previously, various pro-inflammatory cytokines are secreted in the milieu of sIBM inflammatory infiltrates, notably TWEAK <ref type="bibr" target="#b63">[64]</ref>.</s><s>TWEAK induces its effect through its receptor, the fibroblast growth factorinducible gene 14 receptor (Fn14), on neighbouring cells <ref type="bibr" target="#b103">[104]</ref>.</s><s>In sIBM muscle biopsies (but not in dermatomyositis nor in polymyositis) a dysregulation of the TWEAK-Fn14 axis is observed, with an increase of its expression and secretion, which inhibited (in a reversible manner) the myogenic differentiation of mesoangioblasts <ref type="bibr" target="#b63">[64]</ref>.</s><s>TWEAK appeared then as a powerful muscle-wasting cytokine, inducing progressive muscle fibre atrophy, and simultaneously as a negative regulator of regenerative myogenesis <ref type="bibr" target="#b63">[64]</ref>.</s></p><p><s>Moreover, Rigyel et al. <ref type="bibr" target="#b84">[85]</ref> have shown a correlation between the number of invading CD3-positive cells (lymphocytes) or CD68-positive cells (macrophages) and COX-deficient muscle fibres (respectively, p = 0.007 and 0.04).</s><s>These correlations between the degree of inflammation and signs of mitochondrial dysfunction strongly suggest a causative link between them.</s><s>Furthermore, evidence of mitochondrial dysfunction is also highly correlated with fibre atrophy (p &lt; 0.0001) <ref type="bibr" target="#b84">[85]</ref>.</s><s>The authors concluded upon "a role for inflammatory cells in the initiation of mitochondrial DNA damage, which when accumulated causes respiratory dysfunction, fibre atrophy and ultimately degeneration of muscle fibres" <ref type="bibr" target="#b84">[85]</ref>.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>In conclusion: the chicken and the egg: which came first?</head><p><s>From the various arguments summarized above, a possible scenario for the pathogenesis of sIBM, and one that we favour, is that it may start with inflammation within muscle (of unknown aetiology but postulates include viral infections and muscle micro-trauma by eccentric exercise <ref type="bibr" target="#b98">[99]</ref>) with the histological features long considered the hallmark of polymyositis (inflammatory cells, invasion of nonnecrotic muscle fibres, necrotic and regenerating muscle fibres, but without vacuoles or amyloid).</s><s>Interestingly, pure polymyositis (i.e.</s><s>without overlap clinical signs and/or without myositis specific autoantibodies) appears, using current criteria, to be very rare <ref type="bibr" target="#b95">[96]</ref>, being described as an overdiagnosed entity <ref type="bibr" target="#b62">[63]</ref> and even as a mythological beast <ref type="bibr" target="#b2">[3]</ref>.</s></p><p><s>From a clinico-pathological standpoint, Chahin and Engel <ref type="bibr" target="#b23">[24]</ref> showed that in 107 patients whose biopsies were initially read as polymyositis or sIBM, they were able to distinguish, by combining biopsy and clinical criteria, a third group, which they called PM/IBM, with a biopsy diagnosis of polymyositis but with clinical features of sIBM.</s><s>Arguably, this third group only exists because of adherence to earlier diagnostic criteria, and can be understood better if it is accepted that patients with sIBM may not show the currently considered canonical pathological features at an early stage of the disorder.</s><s>Most of the apparently pure polymyositis cases might be, or become, sIBM, representing an intermediate phase falling into the PM/ IBM category <ref type="bibr" target="#b23">[24]</ref>.</s><s>In the same vein, Brady et al. <ref type="bibr" target="#b20">[21]</ref> have shown in a series of 67 sIBM patients that the presence of rimmed vacuoles on muscle biopsy was more common in older patients (74 vs. 66 years; p = 0.04), suggesting that rimmed vacuoles may be a later feature of the disease.</s><s>Moreover, no differences in disease characteristic or progression were observed between patients with or without vacuoles <ref type="bibr" target="#b20">[21]</ref>.</s></p><p><s>The rush of leukocytes, attracted by chemokines and cytokines, may induce fibre injury, mitochondrial dysfunction and HLA class I overexpression through, presumably, components of pro-inflammatory cell stress mechanisms Fig. <ref type="figure">5</ref> A possible scenario for the pathogenesis of sIBM is that it may start with inflammation within muscle (the different actors are represented in red).</s><s>The rush of leukocytes attracted by chemokines and cytokines may induce fibre injury and HLA-I overexpression.</s><s>If the protein degradation systems are overloaded (due to genetic predisposition, particular HLA-I subtypes or ageing), amyloid and other protein deposits (represented in green) may appear within muscle fibres, reinforcing the myopathy in a vicious circle.</s><s>The opposite scenario where amyloid deposits come first leading to a secondary inflammatory reaction is less probable since (apart some rare exceptions) neither hereditary inclusion body myopathy nor animal models of forced amyloid deposits (with proteasomal and/or autophagosomal pathway deficiencies) are accompanied by inflammation such as nitric oxide production <ref type="bibr" target="#b91">[92]</ref>.</s><s>If the protein degradation systems are overloaded (perhaps failing to cope because of genetic predisposition, particular HLA class I subtypes or ageing), amyloid and other protein deposits may appear within muscle fibres, reinforcing the myopathy in a vicious circle, which is clinically manifest as progressive muscle weakness.</s><s>Figure <ref type="figure">5</ref> tries to summarize these hypothetical physiological pathways starting from inflammation: the egg, if we accept that it came first!</s><s>The opposite scenario, where amyloid deposits come first, leading to a secondary inflammatory reaction, is in our opinion, less probable since (apart some rare exceptions) neither hereditary inclusion body myopathy nor animal models of forced amyloid deposits (with proteasomal and/ or autophagosomal pathway deficiencies) are accompanied by inflammation.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1</head><label>1</label><figDesc><div><p><s>Fig. 1 Clinical features of sIBM.</s><s>a Finger flexors weakness (arrow maximum obtained by this patient: 5.6 kg, normal &gt;21 kg for a woman at 70 years old), and b atrophy (arrows).</s><s>c Quadriceps atrophy (arrows) for a man at 75 years old</s></p></div></figDesc><graphic coords="2,85.00,472.05,425.28,209.76" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2</head><label>2</label><figDesc><div><p><s>Fig. 2 Pathological features of sIBM: a partial invasion of a myofiber by inflammatory cells (Gomori trichrome; original magnification ×600).</s><s>b Intracytoplasmic rimmed vacuoles (H&amp;E; original magnification ×400).</s><s>c Evidence of intracytoplasmic and intravacuolar amyloid by staining with pFTAA (original magnification ×400).</s><s>d Intracytoplasmic paired helical filaments illustrated by ultrastructural examination (scale bar represents 0.5 μm).</s><s>e, f Immunohistochemical evidence of P62 + aggregates in muscle fibres (e original magnification ×400, f original magnification ×200)</s></p></div></figDesc><graphic coords="4,204.17,57.76,340.08,360.00" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Fig. 4</head><label>4</label><figDesc><div><p><s>Fig. 4 Composition of the inflammatory infiltrate in sIBM muscle: a CD8 + cells.</s><s>b CD68 + macrophages.</s><s>c CD4 + cells.</s><s>d CD20 + B cells.</s><s>e Clonally Vβ1 expanded cells.</s><s>f CD138 + plasma cells</s></p></div></figDesc><graphic coords="7,204.17,57.76,340.08,384.24" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="5,127.54,57.76,340.20,250.68" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc><div><p></p></div></figDesc><graphic coords="10,116.82,57.76,362.88,253.20" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1</head><label>1</label><figDesc><div><p><s><ref type="bibr" target="#b82">[83]</ref>ENMC IBM Research Diagnostic Criteria 2011[83]</s></p></div></figDesc><table><row><cell>a Demonstration of amyloid or other protein accumulation by established methods (e.g. for amyloid Congo red, crystal violet, thioflavin T/S, for</cell></row><row><cell>other proteins p62, SMI-31, TDP-43). Current evidence favours p62 in terms of sensitivity and specificity but the literature is limited and further</cell></row><row><cell>work required</cell></row></table></figure>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Increased plasma amyloid-beta42 protein in sporadic inclusion body myositis</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">F</forename><surname>Abdo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Van Mierlo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Hengstman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Schelhaas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">G</forename><surname>Van Engelen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Verbeek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Neuropathol</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="429" to="431" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Th1 response and systemic Treg deficiency in inclusion body myositis</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Allenbach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Chaara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rosenzwajg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Six</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Prevel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Mingozzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wanschitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Benveniste</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page">e88788</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Unicorns, dragons, polymyositis, and other mythological beasts</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Amato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Griggs</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="288" to="289" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time. Studies in repeated muscle biopsies</title>
		<author>
			<persName><forename type="first">K</forename><surname>Amemiya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Granger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain</title>
		<imprint>
			<biblScope unit="volume">123</biblScope>
			<biblScope unit="page" from="2030" to="2039" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note>Pt 10</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Allelic heterogeneity of GNE gene mutation in two Tunisian families with autosomal recessive inclusion body myopathy</title>
		<author>
			<persName><forename type="first">R</forename><surname>Amouri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Driss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Murayama</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kefi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Nishino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Hentati</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuromuscul Disord NMD</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="361" to="363" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Increased expression of HLA ABC class I antigens by muscle fibres in Duchenne muscular dystrophy, inflammatory myopathy, and other neuromuscular disorders</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Appleyard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Dunn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Dubowitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Rose</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="issue">8425</biblScope>
			<biblScope unit="page" from="361" to="363" />
			<date type="published" when="1985">1985</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Monoclonal antibody analysis of mononuclear cells in myopathies. I: quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells</title>
		<author>
			<persName><forename type="first">K</forename><surname>Arahata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="193" to="208" />
			<date type="published" when="1984">1984</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<monogr>
		<title level="m" type="main">Sporadic inclusion-body myositis: conformational multifactorial ageing-related degenerative muscle disease associated with proteasomal and lysosomal inhibition, endoplasmic reticulum stress, and accumulation of amyloid-β42 oligomers and phosphorylated tau. Presse Médicale Paris Fr</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<imprint>
			<date type="published" when="1983">2011. 1983</date>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="e219" to="e235" />
		</imprint>
	</monogr>
	<note>Pt 2</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Light and electron microscopic localization of beta-amyloid protein in muscle biopsies of patients with inclusion-body myositis</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">141</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="31" to="36" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Beta-Amyloid protein immunoreactivity in muscle of patients with inclusion-body myositis</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">G</forename><surname>Glenner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">339</biblScope>
			<biblScope unit="page" from="560" to="561" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Twisted tubulofilaments of inclusion body myositis muscle resemble paired helical filaments of Alzheimer brain and contain hyperphosphorylated tau</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bilak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Alvarez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Selkoe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">144</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="177" to="187" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Sporadic inclusion-body myositis: a degenerative muscle disease associated with aging, impaired muscle protein homeostasis and abnormal mitophagy</title>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nogalska</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.bbadis.2014.09.005</idno>
		<idno>doi:10.1016/j. bbadis.2014.09.005</idno>
	</analytic>
	<monogr>
		<title level="j">Biochim Biophys Acta</title>
		<imprint>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Epidemiology of inclusion body myositis in The Netherlands: a nationwide study</title>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">A</forename><surname>Badrising</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maat-Schieman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Van Duinen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1385" to="1387" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo</title>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">A</forename><surname>Badrising</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Maat-Schieman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Ferrari</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="369" to="372" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis</title>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">A</forename><surname>Badrising</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Schreuder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Giphart</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="2396" to="2398" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Translational research and therapeutic perspectives in dysferlinopathies</title>
		<author>
			<persName><forename type="first">F</forename><surname>Barthélémy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Wein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Krahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Lévy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bartoli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Med Camb Mass</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="875" to="882" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Long-term observational study of sporadic inclusion body myositis</title>
		<author>
			<persName><forename type="first">O</forename><surname>Benveniste</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Guiguet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Freebody</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain</title>
		<imprint>
			<biblScope unit="volume">134</biblScope>
			<biblScope unit="page" from="3176" to="3184" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>Pt 11</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Long-term persistence of clonally expanded T cells in patients with polymyositis</title>
		<author>
			<persName><forename type="first">O</forename><surname>Benveniste</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Herson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Salomon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Dimitri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Trebeden-Negre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Jean</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Bon-Durand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Antonelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Klatzmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Boyer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="867" to="872" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">International Workshop on Inclusion Body Myositis held at the Institute of Myology</title>
		<author>
			<persName><forename type="first">O</forename><surname>Benveniste</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hilton-Jones</forename></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuromuscul Disord</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="414" to="421" />
			<date type="published" when="2009">2010. May 2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis</title>
		<author>
			<persName><forename type="first">O</forename><surname>Boyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Saadoun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Abriol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Dodille</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J-C</forename><surname>Piette</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Cacoub</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Klatzmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="3428" to="3430" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features</title>
		<author>
			<persName><forename type="first">S</forename><surname>Brady</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Squier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hilton-Jones</forename></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol Neurosurg Psychiatry</title>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1240" to="1246" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Brady</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Squier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sewry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hanna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hilton-Jones</forename></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Holton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMJ Open</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page">e004552</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Dysferlin is a newly identified binding partner of AβPP and it co-aggregates with amyloid-β42 within sporadic inclusion-body myositis (s-IBM) muscle fibers</title>
		<author>
			<persName><forename type="first">M</forename><surname>Cacciottolo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nogalska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>'agostino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Neuropathol (Berl)</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="781" to="783" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM</title>
		<author>
			<persName><forename type="first">N</forename><surname>Chahin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="418" to="424" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Mutation profile of the GNE gene in Japanese patients with distal myopathy with rimmed vacuoles (GNE myopathy)</title>
		<author>
			<persName><forename type="first">A</forename><surname>Cho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">K</forename><surname>Hayashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Monma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Oya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Noguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Nonaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Nishino</surname></persName>
		</author>
		<idno type="DOI">10.1136/jnnp-2013-305587</idno>
		<idno>doi:10.1136/ jnnp-2013-305587</idno>
	</analytic>
	<monogr>
		<title level="j">J Neurol Neurosurg Psychiatry</title>
		<imprint>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Cox</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Titulaer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Sont</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Wintzen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jjgm</forename><surname>Verschuuren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">A</forename><surname>Badrising</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain J Neurol</title>
		<imprint>
			<biblScope unit="volume">134</biblScope>
			<biblScope unit="page" from="3167" to="3175" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note>Pt 11</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Polymyositis, dermatomyositis and inclusion-body myositis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">325</biblScope>
			<biblScope unit="issue">21</biblScope>
			<biblScope unit="page" from="1487" to="1498" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Koffman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fujii</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Spector</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sivakumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Cupler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="323" to="327" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusionbody myositis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Rakocevic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Schmidt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain</title>
		<imprint>
			<biblScope unit="volume">132</biblScope>
			<biblScope unit="page" from="1536" to="1544" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>Pt 6</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Sonies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dambrosia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Sekul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Cupler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sivakumar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="712" to="716" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Shared blood and muscle CD8+ T-cell expansions in inclusion body myositis</title>
		<author>
			<persName><forename type="first">D</forename><surname>Dimitri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Benveniste</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Dubourg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain</title>
		<imprint>
			<biblScope unit="volume">129</biblScope>
			<biblScope unit="page" from="986" to="995" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note>Pt 4</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Diagnostic value of markers of muscle degeneration in sporadic inclusion body myositis</title>
		<author>
			<persName><forename type="first">O</forename><surname>Dubourg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wanschitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Maisonobe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Béhin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Allenbach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Herson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Benveniste</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Myol Myopathies Cardiomyopathies Off J Mediterr Soc Myol Ed Gaetano Conte Acad Study Striated Muscle Dis</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="103" to="108" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Emslie-Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Arahata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum Pathol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="224" to="231" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Cell stress molecules in the skeletal muscle of GNE myopathy</title>
		<author>
			<persName><forename type="first">C</forename><surname>Fischer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kleinschnitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Wrede</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Muth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Kruse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Nishino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Schmidt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Neurol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">24</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-beta precursor protein-overexpressing cultured human muscle fibers</title>
		<author>
			<persName><forename type="first">P</forename><surname>Fratta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mcferrin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Davies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">167</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="517" to="526" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Overexpression of MHC class I in muscle of lymphocyte-deficient mice causes a severe myopathy with induction of the unfolded protein response</title>
		<author>
			<persName><forename type="first">M</forename><surname>Fréret</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Drouot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Obry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ahmed-Lacheheb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Dauly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Adriouch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cosette</forename><forename type="middle">P</forename><surname>Authier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F-J</forename><surname>Boyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">183</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="893" to="904" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Protein degradation and protection against misfolded or damaged proteins</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Goldberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">426</biblScope>
			<biblScope unit="issue">6968</biblScope>
			<biblScope unit="page" from="895" to="899" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Tragedy in a heartbeat: malfunctioning desmin causes skeletal and cardiac muscle disease</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Goldfarb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="volume">119</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1806" to="1813" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Inclusion body myositis: review of recent literature</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Greenberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Neurol Neurosci Rep</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="83" to="89" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Comment on alemtuzumab and inclusion body myositis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Greenberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain</title>
		<imprint>
			<biblScope unit="volume">133</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note>Pt 5):e135 (author reply e136</note>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Plasma cells in muscle in inclusion body myositis and polymyositis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Greenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Bradshaw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Pinkus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Pinkus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Burleson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Due</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bregoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">S</forename><surname>Bregoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Connor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Amato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1782" to="1787" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Inclusion body myositis and myopathies</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Griggs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Dimauro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Karpati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Mendell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">P</forename><surname>Rowland</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="705" to="713" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Group</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1566" to="1570" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Group</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="718" to="720" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Four-year longitudinal study of clinical and functional endpoints in sporadic inclusion body myositis: Implications for therapeutic trials</title>
		<author>
			<persName><forename type="first">J-Y</forename><surname>Hogrel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Allenbach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Canal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Leroux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ollivier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mariampillai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Servais</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Herson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Decostre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Benveniste</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.nmd.2014.04.009</idno>
		<idno>doi:10.1016/j. nmd.2014.04.009</idno>
	</analytic>
	<monogr>
		<title level="j">Neuromuscul Disord NMD</title>
		<imprint>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Coculture with autologous myotubes of cytotoxic T cells isolated from muscle in inflammatory myopathies</title>
		<author>
			<persName><forename type="first">R</forename><surname>Hohlfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="498" to="507" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Inclusion body myositis: laser microdissection reveals differential up-regulation of IFN-gamma signaling cascade in attacked versus nonattacked myofibers</title>
		<author>
			<persName><forename type="first">J</forename><surname>Ivanidze</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hoffmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lochmuller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hohlfeld</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dornmair</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">179</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="1347" to="1359" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease</title>
		<author>
			<persName><forename type="first">J-S</forename><surname>Ju</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Fuentealba</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jackson</forename><forename type="middle">E</forename><surname>Piwnica-Worms</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Baloh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Weihl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cell Biol</title>
		<imprint>
			<biblScope unit="volume">187</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="875" to="888" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">/VCP at the intersection of the autophagy and the ubiquitin proteasome system</title>
		<author>
			<persName><forename type="first">J-S</forename><surname>Ju</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Weihl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Autophagy</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="283" to="285" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Genetically augmenting Abeta42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice</title>
		<author>
			<persName><forename type="first">M</forename><surname>Kitazawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">N</forename><surname>Green</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Caccamo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Laferla</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">168</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1986" to="1997" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3beta</title>
		<author>
			<persName><forename type="first">M</forename><surname>Kitazawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">N</forename><surname>Trinh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Laferla</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="15" to="24" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Luminescent conjugated oligothiophenes for sensitive fluorescent assignment of protein inclusion bodies</title>
		<author>
			<persName><forename type="first">T</forename><surname>Klingstedt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Blechschmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nogalska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Prokop</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Häggqvist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Danielsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Heppner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Kpr</forename><surname>Nilsson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chembiochem Eur J Chem Biol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="607" to="616" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">HLA allele distribution distinguishes sporadic inclusion body myositis from hereditary inclusion body myopathies</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Koffman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sivakumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Simonis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Stroncek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuroimmunol</title>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="139" to="142" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">A novel homozygous missense mutation in the GNE gene of a patient with quadriceps-sparing hereditary inclusion body myopathy associated with muscle inflammation</title>
		<author>
			<persName><forename type="first">S</forename><surname>Krause</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Schlotter-Weigel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Walter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Najmabadi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wiendl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Muller-Hocker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Muller-Felber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Pongratz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lochmuller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuromuscul Disord</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="830" to="834" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Selective depletion of Foxp3+ regulatory T cells induces a scurfylike disease</title>
		<author>
			<persName><forename type="first">K</forename><surname>Lahl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Loddenkemper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Drouin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Freyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Arnason</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Eberl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hamann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wagner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Huehn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Sparwasser</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Exp Med</title>
		<imprint>
			<biblScope unit="volume">204</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="57" to="63" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Cytosolic 5′-nucleotidase 1A autoimmunity in sporadic inclusion body myositis</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">B</forename><surname>Larman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Salajegheh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Nazareno</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="408" to="418" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapy</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Leff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hicks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">D</forename><surname>Fraser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">H</forename><surname>Plotz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Med Baltim</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="225" to="235" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study</title>
		<author>
			<persName><forename type="first">C</forename><surname>Lindberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Trysberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tarkowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Oldfors</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="260" to="262" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Evaluation and construction of diagnostic criteria for inclusion body myositis</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Lloyd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Mammen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Amato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Weiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Needham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Greenberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="426" to="433" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Beta-amyloid is a substrate of autophagy in sporadic inclusion body myositis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Lunemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Schmid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Barthel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Wrede</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Munz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="476" to="483" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Prophylactic treatment with sialic acid metabolites precludes the development of the myopathic phenotype in the DMRV-hIBM mouse model</title>
		<author>
			<persName><forename type="first">Mcv</forename><surname>Malicdan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Noguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">K</forename><surname>Hayashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Nonaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Nishino</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Med</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="690" to="695" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Mendell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Sahenk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Gales</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Paul</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Neurol</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1229" to="1234" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Polymyositis: an overdiagnosed entity</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Van Der Meulen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">M</forename><surname>Bronner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Hoogendijk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Burger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Van Venrooij</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Voskuyl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Dinant</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Linssen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Wokke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>De Visser</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="316" to="321" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">TWEAK in inclusion-body myositis muscle: possible pathogenic role of a cytokine inhibiting myogenesis</title>
		<author>
			<persName><forename type="first">R</forename><surname>Morosetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gliubizzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sancricca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Broccolini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Gidaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lucchini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mirabella</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">180</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1603" to="1613" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction</title>
		<author>
			<persName><forename type="first">K</forename><surname>Nagaraju</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Casciola-Rosen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Lundberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1824" to="1835" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Conditional up-regulation of MHC class I in skeletal muscle leads to selfsustaining autoimmune myositis and myositis-specific autoantibodies</title>
		<author>
			<persName><forename type="first">K</forename><surname>Nagaraju</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Raben</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Loeffler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="issue">16</biblScope>
			<biblScope unit="page" from="9209" to="9214" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Impaired autophagy in sporadic inclusion-body myositis and in endoplasmic reticulum stress-provoked cultured human muscle fibers</title>
		<author>
			<persName><forename type="first">A</forename><surname>Nogalska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Agostino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Terracciano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Askanas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Pathol</title>
		<imprint>
			<biblScope unit="volume">177</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="1377" to="1387" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">) p62/SQSTM1 is overexpressed and prominently accumulated in inclusions of sporadic inclusionbody myositis muscle fibers, and can help differentiating it from polymyositis and dermatomyositis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Nogalska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Terracciano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>'agostino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
		<author>
			<persName><forename type="first">King</forename><surname>Engel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Askanas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Acta Neuropathol</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="407" to="413" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Expression of mutant ubiquitin (UBB + 1) and p62 in myotilinopathies and desminopathies</title>
		<author>
			<persName><forename type="first">M</forename><surname>Olivé</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Van Leeuwen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Janué</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Moreno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Torrejón-Escribano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Ferrer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropathol Appl Neurobiol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="76" to="87" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">Role of cytokines and chemokines in idiopathic inflammatory myopathies</title>
		<author>
			<persName><forename type="first">B</forename><surname>De Paepe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>Creus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Bleecker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="610" to="616" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">Secretion of amyloidogenic gelsolin progressively compromises protein homeostasis leading to the intracellular aggregation of proteins</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Page</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Suk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bazhenova</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="issue">27</biblScope>
			<biblScope unit="page" from="11125" to="11130" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Expanded T cell receptor Vbeta-restricted T cells from patients with sporadic inclusion body myositis are proinflammatory and cytotoxic CD28null T cells</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Pandya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Fasth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Arnardottir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Dani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lindroos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Malmstrom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">E</forename><surname>Lundberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="3457" to="3466" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">Fast-twitch sarcomeric and glycolytic enzyme protein loss in inclusion body myositis</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Parker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W</forename><surname>Kong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Walsh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Muscle Nerve</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="739" to="753" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">Diagnostic value of MHC class I staining in idiopathic inflammatory myopathies</title>
		<author>
			<persName><forename type="first">J</forename><surname>Van Der Pas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gjd</forename><surname>Hengstman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Ter Laak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">F</forename><surname>Borm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Bgm</forename><surname>Van Engelen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol Neurosurg Psychiatry</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="136" to="139" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">Acquired immune and inflammatory myopathies: pathologic classification</title>
		<author>
			<persName><forename type="first">A</forename><surname>Pestronk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Rheumatol</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="595" to="604" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">Autoantibodies to cytosolic 5′-nucleotidase 1A in inclusion body myositis</title>
		<author>
			<persName><forename type="first">H</forename><surname>Pluk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Bja</forename><surname>Van Hoeve</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Shj</forename><surname>Van Dooren</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="397" to="407" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">Sporadic inclusion body myositis: counts of different types of abnormal fibers</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Pruitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Showalter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Engel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="139" to="143" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">Autoantibodies produced at the site of tissue damage provide evidence of humoral autoimmunity in inclusion body myositis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Ray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Amato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Bradshaw</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page">e46709</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">Ragged red fibers in normal aging and inflammatory myopathy</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Rifai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Welle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Kamp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Thornton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Neurol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="24" to="29" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">Frequency of autoantibodies and correlation with HLA-DRB1 genotype in sporadic inclusion body myositis (s-IBM): a population control study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Rojana-Udomsart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bundell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>James</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Castley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Martinez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Christiansen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Hollingsworth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Mastaglia</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuroimmunol</title>
		<imprint>
			<biblScope unit="volume">249</biblScope>
			<biblScope unit="issue">1-2</biblScope>
			<biblScope unit="page" from="66" to="70" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main">Highresolution HLA-DRB1 genotyping in an Australian inclusion body myositis (s-IBM) cohort: an analysis of disease-associated alleles and diplotypes</title>
		<author>
			<persName><forename type="first">A</forename><surname>Rojana-Udomsart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>James</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Castley</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jneuroim.2012.05.003</idno>
		<idno>doi:10.1016/j. jneuroim.2012.05.003</idno>
	</analytic>
	<monogr>
		<title level="j">J Neuroimmunol</title>
		<imprint>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Rose</surname></persName>
		</author>
		<author>
			<persName><surname>Enmc Ibm Working</surname></persName>
		</author>
		<author>
			<persName><surname>Group</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">188th ENMC International Workshop: Inclusion Body Myositis</title>
				<meeting><address><addrLine>Naarden, The Netherlands</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2011-12">2013. 2-4 December 2011</date>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="1044" to="1055" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Rose</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">ENMC IBM Working Group 188th ENMC International Workshop: Inclusion Body Myositis</title>
				<meeting><address><addrLine>Naarden, The Netherlands</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2011-12">2013. 2-4 December 2011</date>
		</imprint>
	</monogr>
	<note>in press</note>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main">A pilot randomized trial of oxandrolone in inclusion body myositis</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Rutkove</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Parker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Nardin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Connolly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Felice</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Raynor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neurology</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="1081" to="1087" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main">Mitochondrial and inflammatory changes in sporadic inclusion body myositis</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Rygiel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Grady</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Rocha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">W</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Turnbull</surname></persName>
		</author>
		<idno type="DOI">10.1111/nan.12149</idno>
	</analytic>
	<monogr>
		<title level="j">Neuropathol Appl Neurobiol</title>
		<imprint>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main">Autoantibodies against a 43 kDa muscle protein in inclusion body myositis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Salajegheh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Lam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Greenberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page">e20266</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title level="a" type="main">Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Salajegheh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Pinkus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Amato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Nazareno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Baloh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Greenberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Muscle Nerve</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="19" to="31" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main">Misregulation of autophagy and protein degradation systems in myopathies and muscular dystrophies</title>
		<author>
			<persName><forename type="first">M</forename><surname>Sandri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Coletto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Grumati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bonaldo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cell Sci</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page" from="5325" to="5333" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>Pt 23</note>
</biblStruct>

<biblStruct xml:id="b88">
	<analytic>
		<title level="a" type="main">Proteotoxicity: an underappreciated pathology in cardiac disease</title>
		<author>
			<persName><forename type="first">M</forename><surname>Sandri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Robbins</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Mol Cell Cardiol</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="3" to="10" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main">Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle</title>
		<author>
			<persName><forename type="first">J</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Barthel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Wrede</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Salajegheh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bahr</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain</title>
		<imprint>
			<biblScope unit="volume">131</biblScope>
			<biblScope unit="page" from="1228" to="1240" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note>Pt 5</note>
</biblStruct>

<biblStruct xml:id="b90">
	<analytic>
		<title level="a" type="main">Nitric oxide stress in sporadic inclusion body myositis muscle fibres: inhibition of inducible nitric oxide synthase prevents interleukin-1beta-induced accumulation of beta-amyloid and cell death</title>
		<author>
			<persName><forename type="first">J</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Barthel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zschuntzsch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain</title>
		<imprint>
			<biblScope unit="volume">135</biblScope>
			<biblScope unit="page" from="1102" to="1114" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>Pt 4</note>
</biblStruct>

<biblStruct xml:id="b91">
	<analytic>
		<title level="a" type="main">Inclusion body myositis: from immunopathology and degenerative mechanisms to treatment perspectives</title>
		<author>
			<persName><forename type="first">J</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Rev Clin Immunol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1125" to="1133" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b92">
	<analytic>
		<title level="a" type="main">Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicity</title>
		<author>
			<persName><forename type="first">J</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Rakocevic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Raju</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain</title>
		<imprint>
			<biblScope unit="volume">127</biblScope>
			<biblScope unit="page" from="1182" to="1190" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note>Pt 5</note>
</biblStruct>

<biblStruct xml:id="b93">
	<analytic>
		<title level="a" type="main">Hybridoma lupus autoantibodies can bind major cytoskeletal filaments in the absence of DNAbinding activity</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Senécal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rauch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="864" to="875" />
			<date type="published" when="1988">1988</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b94">
	<analytic>
		<title level="a" type="main">Antibody-based proteomics and biomarker research-current status and limitations</title>
		<author>
			<persName><forename type="first">C</forename><surname>Solier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Langen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proteomics</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="774" to="783" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b95">
	<analytic>
		<title level="a" type="main">Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Troyanov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">N</forename><surname>Targoff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Tremblay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Goulet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Raymond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Senecal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Med Baltim</title>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="231" to="249" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b96">
	<analytic>
		<title level="a" type="main">Human monoclonal antibody derived from an autoimmune thrombocytopenic purpura patient, recognizing an intermediate filament&apos;s determinant common to vimentin and desmin</title>
		<author>
			<persName><forename type="first">D</forename><surname>Varon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Linder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Gembom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Guedg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Langbeheim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Berrebi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Eshhar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Immunol Immunopathol</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="454" to="468" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b97">
	<analytic>
		<title level="a" type="main">Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis</title>
		<author>
			<persName><forename type="first">V</forename><surname>Viglietta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Baecher-Allan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Weiner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Hafler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Exp Med</title>
		<imprint>
			<biblScope unit="volume">199</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="971" to="979" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b98">
	<analytic>
		<title level="a" type="main">Variable inflammation and intramuscular STAT3 phosphorylation and myeloperoxidase levels after downhill running</title>
		<author>
			<persName><forename type="first">M</forename><surname>Van De Vyver</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">H</forename><surname>Myburgh</surname></persName>
		</author>
		<idno type="DOI">10.1111/sms.12164</idno>
	</analytic>
	<monogr>
		<title level="j">Scand J Med Sci Sports</title>
		<imprint>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b99">
	<analytic>
		<title level="a" type="main">High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Walter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lochmuller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Toepfer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Schlotter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Reilich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schroder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Muller-Felber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Pongratz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol</title>
		<imprint>
			<biblScope unit="volume">247</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="22" to="28" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b100">
	<analytic>
		<title level="a" type="main">TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Weihl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Temiz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Watts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Forman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">I</forename><surname>Hanson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Kimonis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pestronk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurol Neurosurg Psychiatry</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1186" to="1189" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b101">
	<analytic>
		<title level="a" type="main">Human muscle cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies</title>
		<author>
			<persName><forename type="first">H</forename><surname>Wiendl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mitsdoerffer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Schneider</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Lochmuller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Melms</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Weller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">FASEB J</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">13</biblScope>
			<biblScope unit="page" from="1892" to="1894" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b102">
	<analytic>
		<title level="a" type="main">Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Wildin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Smyk-Pearson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">H</forename><surname>Filipovich</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Med Genet</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="537" to="545" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b103">
	<analytic>
		<title level="a" type="main">TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Wiley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Winkles</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cytokine Growth Factor Rev</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">3-4</biblScope>
			<biblScope unit="page" from="241" to="249" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b104">
	<analytic>
		<title level="a" type="main">Sialyllactose ameliorates myopathic phenotypes in symptomatic GNE myopathy model mice</title>
		<author>
			<persName><forename type="first">T</forename><surname>Yonekawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Mcv</forename><surname>Malicdan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">K</forename><surname>Hayashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Nonaka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Mine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Yamamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Nishino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Noguchi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Brain J Neurol</title>
		<imprint>
			<biblScope unit="volume">137</biblScope>
			<biblScope unit="page" from="2670" to="2679" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>Pt 10</note>
</biblStruct>

<biblStruct xml:id="b105">
	<analytic>
		<title level="a" type="main">Provision of an explanation for the inefficacy of immunotherapy in sporadic inclusion body myositis: quantitative assessment of inflammation and β-amyloid in the muscle</title>
		<author>
			<persName><forename type="first">J</forename><surname>Zschüntzsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Voss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Creus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sehmisch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Raju</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Dalakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Schmidt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arthritis Rheum</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="4094" to="4103" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
